(Q38882388)

7 September 2017

title

Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway (English)

1 reference

7 September 2017

0 references

1 reference

Lugada ES

1

1 reference

7 September 2017

Mermin J

2

1 reference

7 September 2017

Asjo B

3

1 reference

7 September 2017

Kaharuza F

4

1 reference

7 September 2017

Downing R

5

1 reference

7 September 2017

Langeland N

6

1 reference

7 September 2017

Ormaasen V

7

1 reference

7 September 2017

Bruun J

8

1 reference

7 September 2017

Awor AC

9

1 reference

7 September 2017

Ulvestad E

10

1 reference

7 September 2017

publication date

1 February 2004

1 reference

Scandinavian Journal of Immunology

7 September 2017

published in

1 reference

7 September 2017

volume

59

1 reference

7 September 2017

issue

2

1 reference

7 September 2017

page(s)

203-208

1 reference

Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

A two-phase model of B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Prognostic Value of Single Measurements of Beta-2-microglobulin, Immunoglobulin A in HIV Disease After Controlling for CD4 Lymphocyte Counts and Plasma HIV RNA Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0300-9475.2004.01376.X

10.1111/J.0300-9475.2004.01376.X

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference